Patent: 8,932,818
✉ Email this page to a colleague
Summary for Patent: 8,932,818
Title: | Screening assays for compounds that modulate programmed ribosomal frameshifting |
Abstract: | The present invention relates to compounds that modulate ribosomal frameshifting and nucleic acid constructs for use in methods for identifying or validation of compounds that modulate ribosomal frameshifting. In particular, the present invention relates to the use of nucleic acid constructs to identify or validate compounds capable of modulating the efficiency of programmed ribosomal frameshifting and the use of compounds that modulate the efficiency of programmed ribosomal frameshifting to inhibit the replication or infectivity of viruses that employ programmed ribosomal frameshifting. |
Inventor(s): | Paushkin; Sergey V. (Belle Mead, NJ), Naryshkin; Nikolai A. (East Brunswick, NJ), Welch; Ellen (Califon, NJ) |
Assignee: | PTC Therapeutics, Inc. (South Plainfield, NJ) |
Application Number: | 13/058,613 |
Patent Claims: | see list of patent claims |
Details for Patent 8,932,818
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2028-08-13 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2028-08-13 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2028-08-13 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |